RxDoctor Payments Data

Tassia Samona, MD

Internal Medicine · Dearborn, MINPI 1891175048

Payments from drug & device makers

$4,603in general payments, 2019–2025

Across 277 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$616
  • Novo Nordisk$576
  • AstraZeneca$511
  • Amgen$467
  • Lilly USA, LLC$390
  • AbbVie$360
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,603 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$46,437
Medicare patients
209
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$45,859
OzempicSemaglutide40$43,319
JanuviaSitagliptin Phosphate31$32,068
EliquisApixaban29$24,376
TrulicityDulaglutide17$23,981
XareltoRivaroxaban13$15,437
Breo ElliptaFluticasone/Vilanterol17$10,121
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,200
MyrbetriqMirabegron13$7,285
FetzimaLevomilnacipran Hcl12$5,916
PremarinEstrogens, Conjugated11$3,166
PradaxaDabigatran Etexilate Mesylate12$2,232
Atorvastatin Calcium180$2,095
Omeprazole107$1,904
Rosuvastatin Calcium106$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$390$69,84153 claims
Novo NordiskOzempic$576$43,31940 claims
MerckJanuvia$118$32,06831 claims
PfizerEliquis, Premarin$616$27,54240 claims
GSKBreo Ellipta, Trelegy Ellipta$112$18,32130 claims
Astellas Pharma US IncMyrbetriq$200$7,28513 claims
AbbVieFetzima$360$5,91612 claims
Boehringer IngelheimPradaxa$30$2,23212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$40$1,276104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →